FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034301908> ?p ?o ?g. }

• W2034301908 endingPage "233" @default.
• W2034301908 startingPage "227" @default.
• W2034301908 abstract "Laboratory and clinical studies support the concept that heparins, particularly the low molecular component, may serve as an inhibitor of angiogenesis, providing anti-neoplastic effects. Further, treatment with low molecular weight heparin (LMWH) may provide prophylaxis for thromboembolic events (TEE), in glioblastoma (GBM) patients. Dalteparin (5,000 U sub-Q daily) was given with and after conventional radiotherapy to newly diagnosed GBM patients. Forty-five patients were accrued between 5/02 and 9/04; 3 were ineligible. At time of progression, patients could continue dalteparin in addition to standard regimens. Pretreatment characteristics included: median age 61 (range 26–78); ECOG Performance status: 0 = 38%, 1 = 57%, 2 = 5%; gross total resection 45%. There were no grade 3/4 bleeding or thrombocytopenic events, and no TEE occurred while on dalteparin. Median time on dalteparin was 6.3 months, median time to progression was 3.9 months; median survival was 11.9 months. There was no significant improvement in survival when compared to the RTOG GBM database (with various radiation/drug doublets including BCNU) using recursive partitioning analysis. Historically the incidence of TEE in GBM patients is ∼30%. As this study suggests dalteparin reduces the incidence of TEE, and does not have significant overlapping toxicities with most other drugs; its testing in a combined modality approach with other medications may be warranted in future trials." @default.
• W2034301908 created "2016-06-24" @default.
• W2034301908 creator A5003825991 @default.
• W2034301908 creator A5027150108 @default.
• W2034301908 creator A5028489277 @default.
• W2034301908 creator A5036287306 @default.
• W2034301908 creator A5040748530 @default.
• W2034301908 creator A5044365774 @default.
• W2034301908 creator A5064627876 @default.
• W2034301908 date "2007-09-20" @default.
• W2034301908 modified "2023-09-26" @default.
• W2034301908 title "Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial" @default.
• W2034301908 cites W1232974837 @default.
• W2034301908 cites W1482075601 @default.
• W2034301908 cites W1978595239 @default.
• W2034301908 cites W1998260321 @default.
• W2034301908 cites W2001660159 @default.
• W2034301908 cites W2013984355 @default.
• W2034301908 cites W2014671375 @default.
• W2034301908 cites W2028689567 @default.
• W2034301908 cites W2051107088 @default.
• W2034301908 cites W2058727554 @default.
• W2034301908 cites W2059450986 @default.
• W2034301908 cites W2059903449 @default.
• W2034301908 cites W2061015665 @default.
• W2034301908 cites W2093616734 @default.
• W2034301908 cites W2104076622 @default.
• W2034301908 cites W2150648226 @default.
• W2034301908 cites W2157756102 @default.
• W2034301908 cites W2165277386 @default.
• W2034301908 cites W2279412651 @default.
• W2034301908 cites W2403580696 @default.
• W2034301908 cites W2418607702 @default.
• W2034301908 cites W2466556453 @default.
• W2034301908 cites W4293241248 @default.
• W2034301908 doi "https://doi.org/10.1007/s00280-007-0596-3" @default.
• W2034301908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2519795" @default.
• W2034301908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17882417" @default.
• W2034301908 hasPublicationYear "2007" @default.
• W2034301908 type Work @default.
• W2034301908 sameAs 2034301908 @default.
• W2034301908 citedByCount "49" @default.
• W2034301908 countsByYear W20343019082012 @default.
• W2034301908 countsByYear W20343019082013 @default.
• W2034301908 countsByYear W20343019082014 @default.
• W2034301908 countsByYear W20343019082015 @default.
• W2034301908 countsByYear W20343019082016 @default.
• W2034301908 countsByYear W20343019082017 @default.
• W2034301908 countsByYear W20343019082018 @default.
• W2034301908 countsByYear W20343019082019 @default.
• W2034301908 countsByYear W20343019082020 @default.
• W2034301908 countsByYear W20343019082021 @default.
• W2034301908 countsByYear W20343019082022 @default.
• W2034301908 countsByYear W20343019082023 @default.
• W2034301908 crossrefType "journal-article" @default.
• W2034301908 hasAuthorship W2034301908A5003825991 @default.
• W2034301908 hasAuthorship W2034301908A5027150108 @default.
• W2034301908 hasAuthorship W2034301908A5028489277 @default.
• W2034301908 hasAuthorship W2034301908A5036287306 @default.
• W2034301908 hasAuthorship W2034301908A5040748530 @default.
• W2034301908 hasAuthorship W2034301908A5044365774 @default.
• W2034301908 hasAuthorship W2034301908A5064627876 @default.
• W2034301908 hasBestOaLocation W20343019082 @default.
• W2034301908 hasConcept C120665830 @default.
• W2034301908 hasConcept C121332964 @default.
• W2034301908 hasConcept C126322002 @default.
• W2034301908 hasConcept C141071460 @default.
• W2034301908 hasConcept C143998085 @default.
• W2034301908 hasConcept C2776194525 @default.
• W2034301908 hasConcept C2776884760 @default.
• W2034301908 hasConcept C2777557582 @default.
• W2034301908 hasConcept C2778227246 @default.
• W2034301908 hasConcept C502942594 @default.
• W2034301908 hasConcept C509974204 @default.
• W2034301908 hasConcept C535046627 @default.
• W2034301908 hasConcept C61511704 @default.
• W2034301908 hasConcept C71924100 @default.
• W2034301908 hasConceptScore W2034301908C120665830 @default.
• W2034301908 hasConceptScore W2034301908C121332964 @default.
• W2034301908 hasConceptScore W2034301908C126322002 @default.
• W2034301908 hasConceptScore W2034301908C141071460 @default.
• W2034301908 hasConceptScore W2034301908C143998085 @default.
• W2034301908 hasConceptScore W2034301908C2776194525 @default.
• W2034301908 hasConceptScore W2034301908C2776884760 @default.
• W2034301908 hasConceptScore W2034301908C2777557582 @default.
• W2034301908 hasConceptScore W2034301908C2778227246 @default.
• W2034301908 hasConceptScore W2034301908C502942594 @default.
• W2034301908 hasConceptScore W2034301908C509974204 @default.
• W2034301908 hasConceptScore W2034301908C535046627 @default.
• W2034301908 hasConceptScore W2034301908C61511704 @default.
• W2034301908 hasConceptScore W2034301908C71924100 @default.
• W2034301908 hasIssue "2" @default.
• W2034301908 hasLocation W20343019081 @default.
• W2034301908 hasLocation W20343019082 @default.
• W2034301908 hasLocation W20343019083 @default.
• W2034301908 hasLocation W20343019084 @default.
• W2034301908 hasOpenAccess W2034301908 @default.
• W2034301908 hasPrimaryLocation W20343019081 @default.

• next